Citations

Clear

2358 citation(s) found for "Yu, Long".

047 Penile Ring Block Using Long-Acting Liposomal Bupivicaine to Minimize Postoperative Narcotic Use After Surgery for Peyronie's Disease: A Pilot Study
Britton, Cameron J. , Bridget, Fahy, Köhler, Tobias , Ziegelmann, M., Yang, David Y. , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | March 18, 2021 | Volume: 18 | Issue: Supplement_1 | Pages: S26-S26

10.1016/j.jsxm.2021.01.116 Get It

008 Long-term Success with Diminished Opioid Prescribing After Men's Health Urologic Procedures Using Standardized Postoperative Opioid Prescribing Guidelines: An Interrupted Time-Series Analysis
Findlay, B., Britton, Cameron J. , Glasgow, Amy E. , Gettman, Matthew T., Tyson, Mark D. , Pak, Raymond , Ziegelmann, M., Findlay, B., Viers, Boyd R. , Habermann, Elizabeth B.

Mayo Clinic

The Journal of Sexual Medicine | March 18, 2021 | Volume: 18 | Issue: Supplement_1 | Pages: S4-S4

10.1016/j.jsxm.2021.01.078 Get It

Long-term outcomes of grade I/II skull base chondrosarcoma: an insight into the role of surgery and upfront radiotherapy
Hasegawa, Hirotaka , Vakharia, Kunal , Graffeo, Christopher S. , Carlson, Matthew L. , Pollock, Bruce E. , Brown, Paul D. , Perry, Avital , Driscoll, Colin L. W., Link, Michael J., Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

No container title available | March 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-304906/v1 Get It

Abstract PurposeTo clarify the need for post-operative radiation treatment in skull base chondrosarcomas (SBCs).MethodsA retrospective analysis of patients with grade I or II SBC. Patients were divided according to post-surgical treatment strategies: (A) planned upfront radiotherapy and (B) watchful waiting. Tumor control and survival were compared between the treatment groups. The median follow-up after resection was 105 months (range, 9-376).ResultsThirty-two patients (Grade 1, n = 16; Grade 2, n = 16) were included. The most frequent location was petroclival (21, 64%). A gross total resection (GTR) was achieved in 11 patients (34%). Fourteen (44%) underwent upfront radiotherapy (group A) whereas 18 (56%) were followed with serial MRI alone (group B). The tumor control rate for the entire group was 77% and 69% at 10- and 15-year, respectively. Upfront radiotherapy (P = 0.25), extent of resection (P = 0.11) or tumor grade (P = 0.83) did not affect tumor control. The majority of Group B patients with recurrent tumors (5/7) obtained tumor control with repeat resection (n = 2), salvage radiotherapy (n = 2), or a combination of both (n = 1). The 10-year disease-specific survival was 95% with no difference between the group A and B (P = 0.50). ConclusionFor patients with grade I/II SBC, a reasonable strategy is deferral of radiotherapy after maximum safe resection until tumor progression or recurrence. At that time, most patients can be successfully managed with salvage radiotherapy or surgery. Late recurrences may occur, and life-long follow-up is advisable.
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Wenzel, Lari , Osann, Kathryn , McKinney, Chelsea , Cella, David , Fulci, Giulia , Scroggins, Mary Jackson, Lankes, Heather A. , Wang, Victoria , Nephew, Kenneth P. , Maxwell, G. Larry , Mok, Samuel C. , Miller, Austin , Mannel, Robert S., Gray, Heidi J. , Hanjani, Parviz, Huh, Warner K. , Spirtos, Nick M. , Sharma, Sudarshan , Santin, Alessandro D. , Sperduto, Paul W. , Lele, Shashikant B., Burger, Robert A. , Monk, Bradley J. , Birrer, Michael J. , Miller, Austin , Spirtos, Nick , Glaser, Gretchen , Monk, Bradley J , Mok, Samuel C , Conrads, Thomas , Leitão, Mario M. , Glaser, Gretchen

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 15, 2021 | Volume: 113 | Issue: 10 | Pages: 1369-1378

10.1093/jnci/djab034 | PMID 33729494 Get It

Abstract Background There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival. Methods Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (<5 years) of GOG 218 at baseline; before cycles 4, 7, 13, 21; and 6 months post-treatment using linear and longitudinal mixed models adjusted for covariates. Adverse events (AEs) were compared between survivor groups at each assessment using generalized linear models. All P values are 2-sided. Results QOL differed statistically significantly between STS (N = 1115) and LTS (N = 260) (P < .001). Baseline FACT-O-TOI and FACT-O-TOI change were independently associated with long-term survival (odds ratio = 1.05, 95% confidence interval = 1.03 to 1.06 and odds ratio = 1.06, 95% confidence interval = 1.05 to 1.07, respectively). A 7-point increase in baseline QOL was associated with a 38.0% increase in probability of LTS, and a 9-point increase in QOL change was associated with a 67.0% increase in odds for LTS. QOL decreased statistically significantly with increasing AE quartiles (cycle 4 quartiles: 0-5 vs 6-8 vs 9-11 vs ≥12 AEs, P = .01; cycle 21 quartiles: 0-2 vs 3 vs 4-5 vs ≥6 AEs, P = .001). Further, LTS reported statistically significantly better QOL compared with STS (P = .03 and P = .01, cycles 4 and 21, respectively), with similar findings across higher AE grades. Conclusions Baseline and longitudinal QOL change scores distinguished LTS vs STS and are robust prognosticators for long-term survival. Results have trial design and supportive care implications, providing meaningful prognostic value in this understudied population.
Therapeutic Drug Monitoring of Second- and Third-Generation Antiepileptic Drugs
Krasowski, Matthew D., Long, Thomas A., Snozek, Christine L. H., Dizon, Annabel, Magnani, Barbarajean, Melanson, Stacy E. F., Melanson, Stacy E.F. , Krasowski, Matthew D. , Krasowski, Matthew D , Long, Thomas A., Snozek, Christine L. H., Dizon, Annabel, Magnani, Barbarajean

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 15, 2021 | Volume: 145 | Issue: 12 | Pages: 1485-1491

10.5858/arpa.2020-0562-cp | PMID 33720327 Get It

Context.— Therapeutic drug monitoring has traditionally been widely used for first-generation antiepileptic drugs (AEDs) such as carbamazepine and phenytoin. The last 2 decades have seen the introduction of second- and third-generation AEDs (eg, lamotrigine, levetiracetam, and topiramate) into clinical practice. Objective.— To use data from the College of American Pathologists Therapeutic Drug Monitoring, Extended Proficiency Testing Survey to determine the performance of assays used for therapeutic drug monitoring of newer AEDs, including comparison of enzyme immunoassay and chromatographic techniques. Design.— Six years of proficiency testing surveys were reviewed (2013–2018). Results.— Steady growth was seen in participant volumes for newer AEDs. The analytical performance of automated enzyme immunoassays for lamotrigine, levetiracetam, and topiramate was similar to that of chromatographic methods, consistent with published literature using patient samples for comparisons. The majority of participating laboratories now use enzyme immunoassays to measure levetiracetam. Conclusions.— Survey results reflect steadily growing interest in therapeutic drug monitoring of newer AEDs. The increasing availability of robust immunoassays for new AEDs should facilitate their clinical utility, especially for clinical laboratories that do not perform chromatographic assays for therapeutic drug monitoring.
Radiofrequency Ablation for Papillary Thyroid Microcarcinoma Is Safe and Effective in Long-Term Follow-up
Kawkgi, Omar El , Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | March 10, 2021 | Volume: 33 | Issue: 3 | Pages: 121-123

10.1089/ct.2021;33.121-123 Get It

Long-Term Outcomes of Stereotactic Radiosurgery for Trigeminal, Facial, and Jugular Foramen Schwannoma in Comparison with Vestibular Schwannoma
Shinya, Yuki , Hasegawa, Hirotaka , Shin, Masahiro , Sugiyama, Takehiro , Kawashima, Mariko , Katano, Atsuto , Kashio, Akinori , Saito, Nobuhito , Shinya, Yuki , Kondo, Kenji

Mayo Clinic

Cancers | March 7, 2021 | Volume: 13 | Issue: 5 | Pages: 1140

10.3390/cancers13051140 | PMID 33799972 Get It

Stereotactic radiosurgery (SRS) is known to provide excellent tumor control with functional preservation for vestibular schwannomas (VS), but its efficacy in the other major intracranial schwannomas including trigeminal (TS), facial (FS), and jugular foramen schwannomas (JFS) has not been established yet due to their rarity. We retrospectively analyzed data of 514 consecutive patients who had intracranial schwannomas (460 VS, 22 TS, 7 FS, and 25 JFS) and underwent SRS. The 5- and 10-year tumor control rates were 97% and 94% for VS, 100% and 100% for TS, 80% and 80% for FS, and 100% and 80% for JFS. Radiation-induced complications included one hydrocephalus for TS (4.5%), no cases for FS (0%), and one hydrocephalus and one lower palsy for JFS (8.0%). Through matched cohort analysis between patients with VS and each of the non-VS, we found no statistical difference in tumor control and radiation-induced adverse events. SRS seems to provide long-term tumor control with functional preservation for TS, FS and JFS and the efficacies are similar to VS.
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, Emily K. , Bundy, Brian N. , Stier, Kenneth , Serti, Elisavet , Lim, Noha , Long, S. Alice , Geyer, Susan, Moran, Antoinette , Greenbaum, Carla J. , Evans‐Molina, Carmella , Group, Type 1 Diabetes TrialNet Study, DiMeglio, Linda A. , Gitelman, Stephen E. , Gottlieb, Peter A. , Marks, Jennifer B. , Moore, Wayne D. , Rodriguez, Henry , Russell, William E. , Schatz, Desmond , Wherrett, Diane K. , Ziegler, Anette‐Gabriele , Herold, Kevan C , DiMeglio, Linda , Group, Type 1 Diabetes TrialNet Study, Moore, Wayne, Tsalikian, Eva

Mayo Clinic

Science Translational Medicine | March 3, 2021 | Volume: 13 | Issue: 583 | Pages: No page available

10.1126/scitranslmed.abc8980 | PMID 33658358 Get It

Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8 + T cells and improves beta cell function.
Would Women With Solid Organ Transplant Qualify for Triennial Cervical Cancer Screening as Recommended by the American College of Obstetricians and Gynecologists in 2016 and American Society for Colposcopy and Cervical Pathology in 2019?
Long, Margaret E. , Chantigian, Paula D.M., Weaver, Amy L.

Mayo Clinic

Journal of Lower Genital Tract Disease | February 27, 2021 | Volume: 25 | Issue: 2 | Pages: 92-97

10.1097/lgt.0000000000000588 | PMID 33631778 Get It

Objective The aim of the study was to assess the applicability and safety of cervical cancer screening guidelines recommended by the American College of Obstetricians and Gynecologists (2016) and American Society for Colposcopy and Cervical Pathology (2019) for women with solid organ transplants (SOTs). Materials and Methods We analyzed data previously abstracted through December 2015 for 971 women (18–60 y) who received their first SOT at Mayo Clinic (Rochester, MN) from January 17, 1995, through December 31, 2011. Inclusion criteria were initial benign findings on cervical cytology after SOT and at least 1 subsequent cytologic screening. Results Of 415 women whose initial cytologic findings were benign, 310 met inclusion criteria. The cumulative incidence of abnormal cervical cytology among these 310 women was 4.3% (95% CI = 1.9%–6.7%) by 30 months and 11.2% (95% CI = 7.1%–15.4%) by 60 months after their initial benign results. Considering all women with SOT, 68.4% (284/415) had no documented abnormal cytologic findings within 60 months (26 had abnormality; 284 no abnormality; and 105 not assessed). In women with negative tests for human papillomavirus, high-grade squamous intraepithelial lesions were not documented on cytology with variable duration of follow-up. No cervical squamous cell carcinoma was identified. Conclusions Of women with initial benign cervical cytology after SOT, more than two thirds would have been eligible for extended-interval screening. Further study is needed, particularly regarding the role of high-risk human papillomavirus testing.